BioArctic Reports Impressive Q1 2026 Growth and Regulatory Progress for Leqembi®

BioArctic's First Quarter 2026 Results: A Strong Start for Leqembi®

BioArctic AB, a pioneering Swedish biopharmaceutical company, has recently reported a noteworthy performance for the first quarter of 2026. With an impressive financial trajectory and significant strides in regulatory advancements for its lead product, Leqembi® (lecanemab), BioArctic has established itself as a formidable player in the neurodegenerative disease treatment sphere.

Key Financial Outcomes

During the first quarter of 2026, BioArctic reported net revenues amounting to SEK 437.6 million. This figure marks an increase when compared to the SEK 1,289.6 million reported in the same period the previous year, further validating BioArctic's growth trajectory. Among these revenues, SEK 160.8 million stemmed from royalty income resulting from Leqembi, while SEK 218.8 million derived from a milestone payment from Eisai, BioArctic's commercial partner.

Operating profit stood at SEK 210.8 million, with the profit for the period reaching SEK 212.4 million, which translates to earnings per share (EPS) of SEK 2.40 before dilution. These financial results underline the company's robust position and showcase the continued market demand for Leqembi, which has already experienced global sales exceeding EUR 500 million in Eisai's fiscal year 2025. This remarkable sales achievement triggered a further milestone payment of EUR 20 million, underscoring the strong market uptake of the drug.

Regulatory Milestones

One of the major highlights from this reporting period was the regulatory progress related to Leqembi. In January, the FDA granted Priority Review for its supplemental Biologics License Application (sBLA) regarding the subcutaneous formulation of Leqembi for initiating treatment. However, after further review, the FDA extended this review period by three months, setting a new PDUFA date for August 24, 2026.

Additionally, Eisai has submitted an expanded application seeking EU approval for intravenous maintenance treatment with Leqembi, to be administered every four weeks. Notably, China's regulatory authority granted Priority Review for the subcutaneous initiation treatment, signaling a significant international commitment towards making Leqembi more accessible.

Strengthening Evidence for Leqembi

During the recent AD/PD™ conference in Copenhagen, new long-term and real-world data was presented, revealing that patients remained in treatment for extended periods, highlighting the sustained disease-slowing effects over up to four years. This data reinforces our understanding of Alzheimer's disease and showcases the critical importance of providing ongoing care and treatment options to patients and their families.

Despite these advancements, the Swedish NT Council's announcement to not recommend Leqembi's introduction into Swedish healthcare has raised concerns. BioArctic's CEO, Gunilla Osswald, expressed disappointment, emphasizing the urgent need for patients to access cutting-edge treatments, particularly when their efficacy has been well-documented across various global markets.

Future Focus: Parkinson's Disease and Beyond

BioArctic continues to expand its portfolio, notably with ongoing trials for exidavnemab targeting Parkinson's disease and multiple system atrophy. The recruitment for the Phase 2a study of this compound has been successfully completed, and results are eagerly anticipated as the company moves towards Phase 2b.

Moreover, BioArctic is exploring the potential of its proprietary BrainTransporter™ platform, which aims to enhance the delivery of treatments across the blood-brain barrier, thus improving their overall efficacy. With a long-term commitment to neurodegenerative disease treatment, BioArctic remains focused on bringing innovative therapies to market.

Conclusion

As the first quarter of 2026 unfolds, BioArctic stands at the forefront of advancements in Alzheimer’s and related diseases. The company’s strong financial performance, coupled with substantial regulatory progress for Leqembi, underscores its commitment to transforming the landscape of neurodegenerative treatments. With continued efforts in research and a focus on long-term value creation, BioArctic is poised to make a significant impact on the lives of patients affected by these challenging diseases.